Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 28

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 28
---
, with double-digit sales growth for six key assets, including growth of over 50% for Skyrizi and Rinvoq. |

| ● | Reported diluted EPS of $2.39 on a GAAP basis and adjusted diluted EPS of $10.12. See Appendix B for the reconciliation. |

| ● | Generated operating cash flow of $18.8 billion. |

Advancing new medicines and strengthening our innovative R&D pipeline

| ● | Achieved several significant regulatory approvals, including Skyrizi for the treatment of adults with moderately to severely active ulcerative colitis (UC); Vyalev for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD); Epkinly for the treatment of adults with relapsed/refractory (r/r) follicular lymphoma (FL); Elahere for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies; and Botox Cosmetic for temporary improvement in the appearance of moderate to severe platysma bands as well as for the treatment of masseter muscle prominence (MMP). |

| ● | Advanced key late-stage assets with submission of regulatory applications for Rinvoq for the treatment of adults with giant cell arteritis (GCA) and telisotuzumab-vedotin (Teliso-V) for adults with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression as well as positive Phase 3 data for tavapadon as a monotherapy or adjunctive treatment for PD. |

| ● | Strengthened our pipeline with business development, including execution of approximately twenty |

2025 Proxy Statement |35

| ​                      | ​ |
| EXECUTIVE COMPENSATION | ​ |

| collaborations, licensing agreements, or other asset acquisitions. These transactions represent the company’s commitment to invest in research and development that will contribute to AbbVie’s long-term growth. |

Significant long-term value creation

| ​​​                                                                                                                                                         | ​ | ​ | ​​                                                                  | ​ | ​ | ​​​                       |
| ​Market Capitalization                                                                                                                                      | ​ | ​ | ​Quarterly Dividend                                                 | ​ | ​ | ​Total Stockholder Return |
| +$210BN                                                                                                                                                     | ​ | ​ | +235%                                                               | ​ | ​ | +311%                     |
| 10-year increase, adding significant stockholder value